Targeted Therapies in Cancer : Myth or Reality?

This successful Meeting was intended to represent a forum for scientists and clinicians working in cancer drug discovery and therapy to share their reflections and experiences on how the paradigm shift from empiricism to molecular targeted therapies is contributing to the translation of basic knowledge into new therapies for cancer patients.

Causality in Medicine.- The Evolution of the Biomedical Paradigm in Oncology: Implications for Cancer Therapy.- Anticancer Drug Discovery and Development.- Beyond VEGF: Targeting Tumor Growth and Angiogenesis via Alternative Mechanisms.- Aurora Kinases and Their Inhibitors: More Than One Target and One Drug.- Signalling Pathways and Adhesion Molecules as Targets for Antiangiogenesis Therapy in Tumors.- Developing T-Cell Therapies for Cancer in an Academic Setting.- Anticancer Cell Therapy with TRAIL-Armed CD34+ Progenitor Cells.- Linking Inflammation Reactions to Cancer: Novel Targets for Therapeutic Strategies.- Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?.- GIST As the Model of Paradigm Shift Towards Targeted Therapy of Solid Tumors: Update and Perspective on Trial Design.- Monoclonal Antibodies in the Treatment of Malignant Lymphomas.- Molecular Network Analysis using Reverse Phase Protein Microarrays for Patient Tailored Therapy.